This Program Project Grant application seeks support for clinical and experimental studies concerning the major obstacles to successful allogeneic and autologous bone marrow transplantation for hematologic malignancies. These relevant problems include recurrence of the underlying disease, graft-versus host disease and infections with cytomegalovirus and fungus. The program consists of two clinical and seven experimental projects that are supported by three cores. The two clinical projects deal with attempts to eradicate leukemias and lymphomas and prospectively evaluate drug or drug combinations intended to prevent serious transplant-related complications such as acute or chronic GVHD, as well as pharmacologic and immunologic methods to prevent cytomegalovirus disease. In addition, we will introduce radioimmunotherapy utilizing antibodies to leukemia and lymphoma antigens in the preparatory regimen of patients undergoing allogeneic or autologous marrow transplantation for leukemia and myelodysplasia. It is also the intention to use molecular methods to inhibit the Philadelphia chromosome in ALL and to use new methods of gene transduction to study hematopoiesis and lymphopoiesis and to evaluate the source of relapse in patients undergoing autologous marrow transplantation for lymphoma. The two clinical projects serve as a resource for the experimental projects of the program. The seven experimental projects address the following biologically important transplantation related problems and topics: 1) Biological aspects of cytomegalovirus; 2) Acquisition of immunity to cytomegalovirus; 3) Genetic immunization; 4) Development of heavy metal labeled monoclonal antibodies for use in marrow transplantation to treat minimal residual disease; 5) Efficient transduction of hematopoietic stem cells and tumor cells; and 6) Development of ribozymes for the inhibition of malignant cells; These projects attempt to bring innovative concepts to clinical use in the treatment of patients with malignant hematologic disorders. The 8 interrelated projects of this application are supported by three cores, one for biostatistics, one for cytogenetics, and one for administration and coordination of research in this Program Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA030206-17
Application #
2653975
Study Section
Special Emphasis Panel (SRC (DD))
Program Officer
Wu, Roy S
Project Start
1981-07-01
Project End
2000-01-31
Budget Start
1998-09-18
Budget End
1999-01-31
Support Year
17
Fiscal Year
1998
Total Cost
Indirect Cost
Name
City of Hope National Medical Center
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90

Showing the most recent 10 out of 364 publications